FibroGen Inc.
FibroGen Inc. is listed today as Kyntra Bio, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2014 | $20 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Kyntra Bio, Inc., its revenue in fiscal 2025 came from these product and service lines: Drug Product Revenue, Net $5.85 million (91%), Development and Other Revenue $590,000 (9%).
Annual report (SEC XBRL) · Dec 2025
FibroGen Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2014).
SEC Form D · Dec 2014
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Dec 2014
Products and services#
No products or services of FibroGen Inc. are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Astellas Pharma Inc. | Company | not stated | not stated | Held Series D, F and G preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Jorma Routti | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2015) | SEC Form 3 |
| Julian N. Stern | Person | not stated | not stated | Held Series B and F preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Rory B. Riggs | Person | not stated | not stated | Held Series A and F preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Thomas F. Kearns Jr. | Person | not stated | not stated | Held Series RA preferred stock, director (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.
Largest shareholders today
Institutions holding Kyntra Bio, Inc. shares, as of Sep 30, 2026.
- Armistice Capital, LLC$3 M9.88%
- Vanguard Capital Management LLC$1 M3.95%
- Acadian Asset Management LLC$1 M2.61%
- BlackRock, Inc.$1 M2.08%
- Geode Capital Management, LLC$0 M1.02%
- HighTower Advisors, LLC$0 M0.98%
- Renaissance Technologies LLC$0 M0.87%
- Two Sigma Investments, LP$0 M0.77%
- Citadel Advisors LLC$0 M0.60%
- Vanguard Fiduciary Trust Co$0 M0.60%
- Oppenheimer & Co Inc$0 M0.58%
- Birchview Capital, LP$0 M0.56%
- State Street Corp$0 M0.50%
- Gsa Capital Partners LLP$0 M0.50%
- ADAR1 Capital Management, LLC$0 M0.35%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Frank H. Valone | Executive officer | Dec 2014 |
| K. Peony H. Yu | Executive officer | Dec 2014 |
| Pat B. Cotroneo | Executive officer | Dec 2014 |
| Thomas B. Neff | Executive officer | Dec 2014 |
| James A. Schoeneck | Director | Dec 2014 |
| Jorma Pedro Routti | Director | Dec 2014 |
| Julian N. Stern | Director | Dec 2014 |
| Kalevi F. Kurkijarvi | Director | Dec 2014 |
| Miguel F. Madero | Director | Dec 2014 |
| Roberto Pedro Rosenkranz | Director | Dec 2014 |
| Rory B. Riggs | Director | Dec 2014 |
| Thomas B. Neff | Director | Dec 2014 |
| Thomas F. Kearns | Director | Dec 2014 |
| Toshinari N. Tamura | Director | Dec 2014 |
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.